U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Fallopian Tube High Grade Serous Adenocarcinoma

MedGen UID:
1710753
•Concept ID:
C5237039
•
Neoplastic Process
Synonyms: Recurrent Fallopian Tube High-Grade Serous Adenocarcinoma; Recurrent High Grade Fallopian Tube Serous Adenocarcinoma

Definition

The reemergence of fallopian tube high-grade serous adenocarcinoma after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent Fallopian Tube High Grade Serous Adenocarcinoma

Professional guidelines

PubMed

A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.
Bednar EM, Oakley HD, Sun CC, Burke CC, Munsell MF, Westin SN, Lu KH
Gynecol Oncol 2017 Aug;146(2):399-404. Epub 2017 Jun 10 doi: 10.1016/j.ygyno.2017.05.037. PMID: 28610746Free PMC Article
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G
J Clin Oncol 2012 Jul 20;30(21):2654-63. Epub 2012 Jun 18 doi: 10.1200/JCO.2011.39.8545. PMID: 22711857Free PMC Article

Recent clinical studies

Etiology

Comprehensive next-generation sequencing identifies novel putative pathogenic or likely pathogenic germline variants in patients with concurrent tubo-ovarian and endometrial serous and endometrioid carcinomas or precursors.
Aisagbonhi O, Ghlichloo I, Hong DS, Roma A, Fadare O, Eskander R, Saenz C, Fisch KM, Song W
Gynecol Oncol 2024 Aug;187:241-248. Epub 2024 Jun 3 doi: 10.1016/j.ygyno.2024.05.027. PMID: 38833993
Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
AlSomairi A, Himayda S, Altelmesani A, Lee YJ, Lee JY
Gynecol Oncol 2024 Feb;181:155-161. Epub 2024 Jan 3 doi: 10.1016/j.ygyno.2023.12.021. PMID: 38176127
Clinical significance of risk-reducing salpingo-oophorectomy in patients with BRCA1/2 mutation.
Abay M, Ozgen L, Yalcin Y, Ozerkan K
J Gynecol Obstet Hum Reprod 2023 Oct;52(8):102642. Epub 2023 Aug 11 doi: 10.1016/j.jogoh.2023.102642. PMID: 37573025
Genomic catastrophe, the peritoneal cavity and ovarian cancer prevention.
Yoon JY, Chapel DB, Goebel E, Qian X, Mito JK, Horowitz NS, Miron A, Soong TR, Xian W, Crum CP
J Pathol 2022 Jul;257(3):255-261. Epub 2022 Apr 18 doi: 10.1002/path.5891. PMID: 35238033
Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior.
Reyes HD, Devor EJ, Warrier A, Newtson AM, Mattson J, Wagner V, Duncan GN, Leslie KK, Gonzalez-Bosquet J
Sci Rep 2019 Nov 29;9(1):17996. doi: 10.1038/s41598-019-54401-w. PMID: 31784612Free PMC Article

Diagnosis

Comprehensive next-generation sequencing identifies novel putative pathogenic or likely pathogenic germline variants in patients with concurrent tubo-ovarian and endometrial serous and endometrioid carcinomas or precursors.
Aisagbonhi O, Ghlichloo I, Hong DS, Roma A, Fadare O, Eskander R, Saenz C, Fisch KM, Song W
Gynecol Oncol 2024 Aug;187:241-248. Epub 2024 Jun 3 doi: 10.1016/j.ygyno.2024.05.027. PMID: 38833993
Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
AlSomairi A, Himayda S, Altelmesani A, Lee YJ, Lee JY
Gynecol Oncol 2024 Feb;181:155-161. Epub 2024 Jan 3 doi: 10.1016/j.ygyno.2023.12.021. PMID: 38176127
Clinical significance of risk-reducing salpingo-oophorectomy in patients with BRCA1/2 mutation.
Abay M, Ozgen L, Yalcin Y, Ozerkan K
J Gynecol Obstet Hum Reprod 2023 Oct;52(8):102642. Epub 2023 Aug 11 doi: 10.1016/j.jogoh.2023.102642. PMID: 37573025
The Many Microenvironments of Ovarian Cancer.
Micek HM, Visetsouk MR, Fleszar AJ, Kreeger PK
Adv Exp Med Biol 2020;1296:199-213. doi: 10.1007/978-3-030-59038-3_12. PMID: 34185294Free PMC Article
Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.
Dao F, Schlappe BA, Tseng J, Lester J, Nick AM, Lutgendorf SK, McMeekin S, Coleman RL, Moore KN, Karlan BY, Sood AK, Levine DA
Gynecol Oncol 2016 May;141(2):260-263. Epub 2016 Mar 11 doi: 10.1016/j.ygyno.2016.03.010. PMID: 26968641Free PMC Article

Therapy

Artificial intelligence-based image analysis can predict outcome in high-grade serous carcinoma via histology alone.
Laury AR, Blom S, Ropponen T, Virtanen A, Carpén OM
Sci Rep 2021 Sep 27;11(1):19165. doi: 10.1038/s41598-021-98480-0. PMID: 34580357Free PMC Article
Chemotherapy-associated foam cell aggregates as a prognostic factor in patients with pelvic high-grade serous carcinoma receiving neo-adjuvant chemotherapy.
Kojima N, Kuno I, Ushigusa T, Kato T, Yoshida H
Virchows Arch 2020 Sep;477(3):429-436. Epub 2020 Feb 26 doi: 10.1007/s00428-020-02778-9. PMID: 32103350
Chemotherapy is of Value in Second Line and Beyond, Relapsed High-grade, Serous Epithelial Ovarian Cancer: An Analysis of Outcomes Obtained With Oral Etoposide.
Kumar A, Le N, Santos J, Hoskins P
Am J Clin Oncol 2018 Apr;41(4):379-384. doi: 10.1097/COC.0000000000000281. PMID: 26999277
Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma.
Coghlan E, Meniawy TM, Munro A, Bulsara M, Stewart CJ, Tan A, Koay MHE, MaGee D, Codde J, Tan J, Salfinger SG, Mohan GR, Leung Y, Nichols CB, Cohen PA
Int J Gynecol Cancer 2017 May;27(4):708-713. doi: 10.1097/IGC.0000000000000945. PMID: 28441251
Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.
Ahmed N, Abubaker K, Findlay J, Quinn M
J Cell Biochem 2013 Jan;114(1):21-34. doi: 10.1002/jcb.24317. PMID: 22887554

Prognosis

Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
AlSomairi A, Himayda S, Altelmesani A, Lee YJ, Lee JY
Gynecol Oncol 2024 Feb;181:155-161. Epub 2024 Jan 3 doi: 10.1016/j.ygyno.2023.12.021. PMID: 38176127
Artificial intelligence-based image analysis can predict outcome in high-grade serous carcinoma via histology alone.
Laury AR, Blom S, Ropponen T, Virtanen A, Carpén OM
Sci Rep 2021 Sep 27;11(1):19165. doi: 10.1038/s41598-021-98480-0. PMID: 34580357Free PMC Article
The Many Microenvironments of Ovarian Cancer.
Micek HM, Visetsouk MR, Fleszar AJ, Kreeger PK
Adv Exp Med Biol 2020;1296:199-213. doi: 10.1007/978-3-030-59038-3_12. PMID: 34185294Free PMC Article
ReMixT: clone-specific genomic structure estimation in cancer.
McPherson AW, Roth A, Ha G, Chauve C, Steif A, de Souza CPE, Eirew P, Bouchard-Côté A, Aparicio S, Sahinalp SC, Shah SP
Genome Biol 2017 Jul 27;18(1):140. doi: 10.1186/s13059-017-1267-2. PMID: 28750660Free PMC Article
Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer.
McPherson A, Roth A, Laks E, Masud T, Bashashati A, Zhang AW, Ha G, Biele J, Yap D, Wan A, Prentice LM, Khattra J, Smith MA, Nielsen CB, Mullaly SC, Kalloger S, Karnezis A, Shumansky K, Siu C, Rosner J, Chan HL, Ho J, Melnyk N, Senz J, Yang W, Moore R, Mungall AJ, Marra MA, Bouchard-Côté A, Gilks CB, Huntsman DG, McAlpine JN, Aparicio S, Shah SP
Nat Genet 2016 Jul;48(7):758-67. Epub 2016 May 16 doi: 10.1038/ng.3573. PMID: 27182968

Clinical prediction guides

Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
AlSomairi A, Himayda S, Altelmesani A, Lee YJ, Lee JY
Gynecol Oncol 2024 Feb;181:155-161. Epub 2024 Jan 3 doi: 10.1016/j.ygyno.2023.12.021. PMID: 38176127
Genomic catastrophe, the peritoneal cavity and ovarian cancer prevention.
Yoon JY, Chapel DB, Goebel E, Qian X, Mito JK, Horowitz NS, Miron A, Soong TR, Xian W, Crum CP
J Pathol 2022 Jul;257(3):255-261. Epub 2022 Apr 18 doi: 10.1002/path.5891. PMID: 35238033
Artificial intelligence-based image analysis can predict outcome in high-grade serous carcinoma via histology alone.
Laury AR, Blom S, Ropponen T, Virtanen A, Carpén OM
Sci Rep 2021 Sep 27;11(1):19165. doi: 10.1038/s41598-021-98480-0. PMID: 34580357Free PMC Article
Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior.
Reyes HD, Devor EJ, Warrier A, Newtson AM, Mattson J, Wagner V, Duncan GN, Leslie KK, Gonzalez-Bosquet J
Sci Rep 2019 Nov 29;9(1):17996. doi: 10.1038/s41598-019-54401-w. PMID: 31784612Free PMC Article
ReMixT: clone-specific genomic structure estimation in cancer.
McPherson AW, Roth A, Ha G, Chauve C, Steif A, de Souza CPE, Eirew P, Bouchard-Côté A, Aparicio S, Sahinalp SC, Shah SP
Genome Biol 2017 Jul 27;18(1):140. doi: 10.1186/s13059-017-1267-2. PMID: 28750660Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...